WO2017201082A1 - Valvule cardiaque transcathéter en couche mince - Google Patents

Valvule cardiaque transcathéter en couche mince Download PDF

Info

Publication number
WO2017201082A1
WO2017201082A1 PCT/US2017/032958 US2017032958W WO2017201082A1 WO 2017201082 A1 WO2017201082 A1 WO 2017201082A1 US 2017032958 W US2017032958 W US 2017032958W WO 2017201082 A1 WO2017201082 A1 WO 2017201082A1
Authority
WO
WIPO (PCT)
Prior art keywords
thin
film
fenestrated
microns
heart valve
Prior art date
Application number
PCT/US2017/032958
Other languages
English (en)
Inventor
Colin Kealey
Vikas Gupta
Ian Cook
Original Assignee
Nsvascular, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsvascular, Inc. filed Critical Nsvascular, Inc.
Priority to GB1820077.4A priority Critical patent/GB2565028B/en
Publication of WO2017201082A1 publication Critical patent/WO2017201082A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2415—Manufacturing methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418—Scaffolds therefor, e.g. support stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/04—Metals or alloys
    • A61L27/06—Titanium or titanium alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes

Definitions

  • the present disclosure generally relates to transcatheter heart valves and, more particularly, to transcatheter heart valves that include a fenestrated thin-film.
  • Transcatheter aortic valve replacement is well-established as the standard of care for patients with severe symptomatic aortic stenosis who are not candidates for surgery. In these procedures, the diseased valve is not removed but is instead crushed by a superimposed stent-based, bioprosthetic valve.
  • a known complication of the procedure is paravalvular leak (PVL), where there is an incomplete seal between the aortic annulus and the bioprosthetic valve. PVL is common post transcatheter valve placement with a reported incidence between 50% and 85%. Further it is known that moderate to severe PVL is an independent predictor of mortality in the post-operative period to 30 days, as well as at 1 and 2-year follow-up.
  • Figure 1 is a perspective view of a conventional transcatheter heart valve.
  • Figure 2 is a perspective view of a thin-film transcatheter heart valve according to an embodiment of the present disclosure.
  • Figure 3 A is a plan view of an etched semiconductor wafer for making a thin-film mesh cover for a transcatheter heart valve.
  • Figure 3B is a cross-sectional view of the wafer of Figure 3 A along lines D:D.
  • Figure 4A is a perspective view of a portion of a thin-film mesh cover prior to expansion.
  • Figure 4B is a plan view of a portion of a thin-film mesh cover after expansion.
  • Figure 5 illustrates a method for forming the thin-film mesh cover of Figure 2 using a three-dimensional thin-film mesh.
  • Figure 6 illustrates a method for forming the thin-film mesh cover of Figure 2 using a two-dimensional thin-film mesh.
  • Figure 7A is an image showing results of a conventional braided stent implanted at a model aneurysm in a rabbit.
  • Figure 7B is an image showing results of a thin-film Nitinol covered stent with a lower pore density implanted at a model aneurysm in a rabbit.
  • Figure 7C is an image showing results of a thin-film Nitinol covered stent with a higher pore density implanted at the model aneurysm in a rabbit.
  • One or more embodiments of the present disclosure provide improved transcatheter heart valves that incorporate a fenestrated thin-film covering and related methods.
  • the thin-film covering facilitates incorporation of the prosthetic valve into the surrounding tissue.
  • Better incorporation of the valve into the surrounding tissue advantageously reduces the incidence of paravalvular leak (PVL), which is a significant improvement over conventional transcatheter heart valves.
  • PVL paravalvular leak
  • a thin-film mesh (also referred to as a fenestrated thin-film or a fenestrated thin-film sheet) is defined to be less than 100 microns in thickness (e.g., between 2 and 30 microns in thickness).
  • An example thin-film mesh comprises fenestrated thin-film Nitinol (TEN), although other thin-film mesh materials may be used to form the transcatheter heart valve disclosed herein.
  • TEN thin-film Nitinol
  • Example fenestrated thin-film Nitinol is disclosed in commonly-assigned International Application No. PCT US2014/61836 (the "PCT application”), filed October 22, 2014, which in turn claims the benefit of U.S.
  • Nitinol NiTi
  • the patterned mesh may then be removed using a lift-off process by etching away a sacrificial layer such as a chromium layer to form a two-dimensional (2D) thin-film mesh.
  • a sheet of fenestrated thin-film Nitinol may be disposed about a transcatheter heart valve and attached, for example, by soldering, by an adhesive (e.g., glue), by fastening with a wire or string, and/or by stitches.
  • this lift-off process is combined with multiple-layer depositions of Nitinol separated by layers of sacrificial material to fabricate cylindrical a thin-film mesh, which are three-dimensional (3D) in the sense that two layers are joined together along their longitudinal edges such that the resulting joined layers may be opened up to form a cylinder.
  • 3D three-dimensional fabrication techniques
  • the three-dimensional fabrication techniques disclosed in the PCT application may be used to manufacture a circumferential ring of thin-film Nitinol, which would then be attached to the transcatheter heart valve.
  • a conventional transcatheter heart valve 100 is shown in Figure 1A.
  • Transcatheter heart valve includes a stent support structure 105 that may either be self- expandable or balloon expandable, a bioprosthetic valve 110, and an outer covering 115 (also referred to as an outer cover).
  • Stent support structure 105 may be composed of an alloy frame (e.g., Nitinol alloy frame, a cobalt chromium frame, or other alloy frame).
  • Outer covering 115 may be composed of a polymer such polyethylene terephthalate (PET), polytetrafluoroethylene (PTFE), or other polymer.
  • Outer covering 115 may also be composed a biologically derived tissues such as decellularized pericardium from a porcine or bovine source.
  • outer covering 115 When implanted in a patient, outer covering 115 sits in the patient's aortic annulus.
  • outer coverings 115 made of polymers (e.g., PET, PTFE, or other polymer) or biologically derived tissues are impermeable or only semi-permeable membranes and, thus, do not sufficiently endotheliahze or facilitate robust tissue in-growth. This may be responsible for the high incidence of PVL observed in transcatheter heart valves.
  • a thin-film mesh covering 215 (also referred to as a thin-film mesh cover or a thin-film mesh addition) is attached to stent support structure 105, as shown by thin-film transcatheter heart valve 200 in Figure 2.
  • Thin-film mesh covering 215 replaces outer covering 115 of conventional transcatheter heart valve 100.
  • thin-film transcatheter heart valve 200 includes stent support structure 105, bioprosthetic valve 110, and thin-film mesh covering 215.
  • Thin-film mesh covering 215 facilitates rapid tissue in-growth and endothelialization of endovascular implants.
  • thin-film transcatheter heart valve 200 includes both outer covering 115 and thin-film mesh covering 215, with thin-film mesh covering 215 disposed on the outer surface of outer covering 115 (not shown).
  • thin-film mesh covering 215 is attached to stent support structure 105 by soldering (e.g., soldering with a low temperature solder), by fastening with a wire or string, by an adhesive (e.g., glue), or by stitches.
  • soldering e.g., soldering with a low temperature solder
  • an adhesive e.g., glue
  • thin-film mesh covering 215 is attached to stent support structure 105 by a wire or string.
  • thin-film mesh covering 215 is attached to stent support structure 105 using other fastening methods as appropriate.
  • thin-film mesh covering 215 may be formed using a deep- reactive ion etched semiconductor wafer as described in the PCT application.
  • Figure 3A is a plan view of a substrate such as an etched wafer 300 formed by using a deep reactive-ion etching (DRIE) process. Grooves 305 are separated by lands 310. Rows of grooves 305 are displaced with respect to adjacent rows of grooves 305 such that a groove 305 in one row is longitudinally displaced by approximately 50 % with regard to the neighboring grooves in the immediately- adjacent grooves.
  • Figure 3B illustrates a cross-section of etched wafer 300. Grooves 305 are separated by lands 310.
  • the width of lands 310 may be 1 to 30 microns (e.g., between 4 and 30 microns, between 4 and 20 microns, between 1 and 20 microns, approximately 10 microns, etc.) in some embodiments.
  • the width of grooves 305 may be 1 to 30 microns (e.g., between 4 and 30 microns, between 4 and 20 microns, between 1 and 20 microns, approximately 10 microns, etc.).
  • the longitudinal extent of each groove 305 may range from a few microns to approximately 500 microns (e.g., between 100 microns and 500 microns, between 100 microns and 400 microns, between 100 microns and 300 microns, between 150 microns and 400 microns, etc.).
  • Nitinol may then be deposited on etched wafer 300 to a thickness of
  • each fiche or pattern of fenestrations effectively codes for the resulting fenestrations when the stent cover is expanded to fully open up the fenestrations.
  • FIG. 4A shows two fenestrations 400 in a portion of a thin-film mesh 405 prior to expansion.
  • mesh 405 is expanded in the lateral direction 410 (also referred to as the axis of expansion of mesh 405) orthogonal to the longitudinal axis of fenestrations 400 (also referred to as the longitudinal direction or long axis of fenestrations 400) such that fenestrations 400 open up into a "chain- link" fence pattern of diamond-shaped fenestrations.
  • fenestration shapes may be used in alternative embodiments.
  • the expansion may extend mesh 405 in a range from 100% to 800%
  • Thin-film mesh 405 as fabricated has fenestrations 400 that duplicate grooves 305 of wafer 300, and struts 415 that duplicate lands 310 of wafer 300.
  • the longitudinal extent of each fenestration 400 may range from a few microns to approximately 500 microns (e.g., between 100 microns and 500 microns, between 100 microns and 400 microns, between 100 microns and 300 microns, between 150 microns and 400 microns, etc.).
  • Struts 415 may have a thickness of between 1 and 30 microns (e.g., between 4 and 30 microns, between 4 and 20 microns, between 2 and 20 microns, approximately 10 microns, etc.) prior to and after expansion.
  • Thin-film mesh covering 215 may include fenestrations having a longitudinal axis that is parallel to the longitudinal axis of stent support structure 105 (also referred to as the longitudinal direction of stent support structure 105). Accordingly, thin-film mesh covering 215 may be fabricated to be expandable in the radial direction. When thin- film mesh covering 215 is expanded, a radius of the circular cross-section of thin-film mesh covering 215 may be equal or approximately equal to a radius of the circular cross-section of stent support structure 105.
  • thin-film mesh covering 215 may include fenestrations having a longitudinal axis that is orthogonal to the longitudinal axis of stent support structure 105. Accordingly, thin-film mesh covering 215 may be expandable in the longitudinal axis of stent support structure 105.
  • the resulting high pore density, fenestrations per square mm, (e.g., between 81 and 1075 pores per mm 2 , between 134 and 227 pores per mm 2 , between 81 and 227 pores per mm 2 , etc.) and low metal coverage (e.g., between 19 and 66%, between 24 and 36%, between 19% and 36%, etc.) is very advantageous with regard to promoting a planar deposition of fibrin followed by a rapid endothelialization.
  • thin-film mesh covering 215 shown in Figure 2 is incorporated into the blood vessel endothelial lining, which thus seals the end of thin- film transcatheter heart valve to prevent PVL.
  • Thin-film meshes such as thin-film mesh 405, orientation of fenestrations, and various parameters for thin-film meshes relating to fenestrations such as fenestrations 405, struts such as struts 415, pore density, percent metal coverage, strut angle, and other features of the thin-film meshes may be implemented in accordance with the techniques described in U.S. Provisional Application No. 62/148,689, previously referenced herein.
  • the biological seal of the endothelium also serves to anchor thin-film transcatheter heart valve 200.
  • thin-film transcatheter heart valve 200 is stabilized mechanically, thereby mitigating the issue of migration. Notably, this is accomplished without damage to the vessel wall or adjacent structures.
  • Figure 5 illustrates a method 500 for forming thin-film transcatheter heart valve 200 using a three-dimensional thin-film mesh.
  • a first sacrificial layer (e.g., a lift-off or release layer) of Cr (or other sacrificial or barrier layers) is deposited on a silicon substrate (e.g., silicon wafer substrate 300), for example, in a sputtering chamber while the substrate is held at high vacuum or under ultrahigh vacuum, using e-beam evaporation or PECVD.
  • the liftoff layer may release the finished product such as thin-film mesh covering 215 from the substrate (e.g., silicon wafer substrate 300) and may thus be referred to as a release layer.
  • the lift-off layer may be 1700 to 3000 Angstroms of sputter-deposited chromium.
  • Step 501 and one or more of subsequent steps 502 through 504 may all be performed while the substrate continues to be held under a vacuum in a sputtering chamber and without removing the vacuum (or removing the substrate wafer or device from the vacuum chamber) until all depositions are completed.
  • the substrate may first (e.g., before deposition) be prepared in step 501 by etching (using, for example, dry etching or DRIE) grooves or trenches that will correspond to fenestrations 400 of the web fiche pattern or other surface features that may correspond to structures (e.g., mesh fenestrations) of a finished product such as thin-film mesh covering 215.
  • etching using, for example, dry etching or DRIE
  • a first layer of NiTi may be deposited using one or more sputtering or other techniques.
  • An example thickness of this first layer (as well as the second layer of NiTi) is between 2 and 30 microns in thickness (e.g., 3 to 5 microns).
  • a second sacrificial layer of Cr may be deposited on the silicon substrate (e.g., silicon wafer substrate 300), for example, in a sputtering (or vacuum) chamber while the substrate continues to be held at high vacuum or under ultra-high vacuum, using e-beam evaporation or PECVD.
  • a shadow mask may be placed over the substrate and the previously deposited layers such as the release layer and the first NiTi layer prior to depositing the second sacrificial layer to protect covered (or blocked) areas from deposition of the second Cr sacrificial layer (or other sacrificial or barrier layers).
  • the shadow mask may be removed from the substrate and the accumulated deposited layers after depositing the second sacrificial layer.
  • an aluminum bonding layer is applied using a reverse mask to prevent formation of an oxidized surface layer on the first NiTi layer.
  • the reverse mask (as implied by the name) is the complement of the shadow mask used to form the second sacrificial layer. In other words, the reverse mask covers the second sacrificial layer and exposes the uncovered areas of the first NiTi layer. Aluminum may then be sputtered through the reverse mask to form the bonding layer.
  • the first NiTi layer may be exposed to the atmosphere between the masking with the shadow mask and the subsequent masking with the reverse mask. In this fashion, manufacturing costs are lowered in that the applications of the masks is greatly aided by performing the mask applications outside of the vacuum chamber using, for example, conventional semiconductor pick-and-place equipment.
  • the first NiTi layer may be maintained in a vacuum or an ultra-high vacuum until a second layer of NiTi is deposited, including during the application and removal of the shadow mask.
  • a second layer of NiTi may be deposited using one or more sputtering or other techniques.
  • deposition of the second layer of NiTi may result in the second layer of NiTi bonding to the first layer of NiTi at those areas left exposed by the second sacrificial layer, forming, for example, bonds at the edges of thin-film mesh covering 215.
  • wafer 300 may be heated to approximately 500 to 600 degrees prior to removal of the lift-off and sacrificial layers at step 506. Such heating partially melts the aluminum, which then becomes very reactive despite the formation of some aluminum oxides. The molten un-oxidized aluminum is very reactive and chemically bonds to the NiTi layers, resulting in a very secure bond, despite the formation of an oxidized NiTi surface on the first NiTi layer.
  • removal of the sacrificial layers may be performed using a wet etch and may be performed after allowing the vacuum chamber to repressurize or after removing substrate 300 from the vacuum chamber.
  • Etching the sacrificial layers may release thin-film mesh covering 215 from the substrate and may remove interior layers such as the second sacrificial layer.
  • the etch may comprise soaking silicon substrate wafer 300 and the deposited layers in a solution, for example, of Cr etch, and may create a lumen where sacrificial layers are removed between the first and second NiTi layers that are joined at the edges.
  • thin-film mesh covering 215 is expanded such that fenestrations 400 open up into a "chain-link" fence pattern of diamond-shaped fenestrations. Further processing may be performed, such as shaping thin-film mesh covering 215 including, for example, shaping thin-film mesh covering 215 into a more cylindrical shape by insertion of a mandrel into the lumen. With thin-film mesh covering 215 in the desired shape, the NiTi layers may be crystallized. Steps 501-506 are further described in the PCT application.
  • thin-film mesh covering 215 is attached to stent support structure 105 to form a thin-film transcatheter heart valve such as thin-film transcatheter heart valve 200 of Figure 2.
  • Thin-film mesh covering 215 may be attached to stent support structure 105 by soldering, by an adhesive such as glue, by fastening with a wire or string, by stitches, and/or other fastening methods as appropriate.
  • Thin-film transcatheter heart valve 200 may then be implanted in a patient using a transcatheter heart valve delivery system.
  • FIG. 6 illustrates a method 600 for forming thin-film transcatheter heart valve 200 using two-dimensional thin-film meshes.
  • a sacrificial layer e.g., a lift-off or release layer
  • Cr or other sacrificial or barrier layers
  • the substrate may first (e.g., before deposition) be prepared in step 601 by etching (using, for example, dry etching or DRIE) grooves or trenches that will correspond to fenestrations 400 of the web fiche pattern or other surface features that may correspond to structures (e.g., mesh fenestrations) of a finished product such as thin-film mesh covering 215.
  • etching using, for example, dry etching or DRIE
  • a layer of NiTi may be deposited using one or more sputtering or other techniques.
  • An example thickness of this first layer (as well as the second layer of NiTi) is between 2 and 30 microns in thickness (e.g., 3 to 5 microns).
  • removal of the sacrificial layers may be performed using a wet etch and may be performed after allowing the vacuum chamber to repressurize or after removing substrate 300 from the vacuum chamber.
  • Etching the sacrificial layers may release thin-film mesh covering 215 from the substrate.
  • the etch may comprise soaking silicon substrate wafer 300 and the deposited layers in a solution, for example, of Cr etch.
  • thin-film mesh covering 215 is expanded such that fenestrations 400 open up into a "chain-link" fence pattern of diamond-shaped fenestrations. Further processing may be performed, such as shaping thin-film mesh covering 215 including, for example, shaping thin-film mesh covering 215 into a more cylindrical shape by annealing on a mandrel. With thin- film mesh covering 215 in the desired shape, the NiTi layers may be crystallized.
  • thin-film mesh covering 215 is attached to stent support structure 105 to form a thin-film transcatheter heart valve such as thin-film transcatheter heart valve 200 of Figure 2.
  • Thin-film mesh covering 215 may be attached to stent support structure 105 by soldering, by an adhesive such as glue, by fastening with a wire or string, or other fastening methods as appropriate.
  • Thin-film transcatheter heart valve 200 may then be implanted in a patient using a transcatheter heart valve delivery system.
  • Thin-film mesh covering 215 formed using the techniques described herein is planar with regard to the wire intersections.
  • the columnar fenestrations may be expanded into diamond shapes (e.g., having a length of approximately 300 microns and a width of approximately 150 microns).
  • the resulting wire forming the diamond-shaped fenestrations is only 2 to 30 microns in thickness.
  • Each "corner" of the diamond-shaped fenestration is thus relatively flat such that a null region with regard to fluid flow is formed at each corner. This may be better appreciated with regard to Figure 4B, which shows the diamond-shaped fenestrations that result upon expansion.
  • the thin- film mesh 405 forms flat interstices that are advantageously conducive to the desired clotting process so that flow diversion of aneurysm is safely achieved.
  • Such interstices are absent in a conventional wire mesh because of the weaving of the relatively coarse wire.
  • Endovascular implants that include thin-film Nitinol meshes facilitate robust endothelialization and tissue in-growth and, as such, thin-film Nitinol meshes may be advantageously used to improve transcatheter heart valves.
  • a conventional braided stent, a thin- film Nitinol covered stent with a lower pore density, and a thin-film Nitinol covered stent with a higher pore density were tested by implanting in model aneurysms created in rabbits. The animals were then sacrificed after several weeks and the degree of aneurysm neck healing was examined by removing the arterial vessel segments containing the devices and the model aneurysms for pathological analysis.
  • FIG. 7A is an image showing results of the conventional braided stent 4 weeks after implanting at the model aneurysm in a rabbit.
  • the conventional braided stent had a pore density of about 14 pores/mm 2 as implanted.
  • Figure 7B is an image showing results of the thin-film Nitinol covered stent having a lower pore density 8 weeks after implanting at the model aneurysm in a rabbit.
  • the thin-film Nitinol was fabricated with a slit length of approximately 300 ⁇ .
  • the thin-film Nitinol had a pore density of approximately 70 pores/mm 2 as implanted.
  • the thin-film Nitinol had a pore density may range from 38 to 70 pores/mm 2 when the strut angle (angle between two struts) is between 30 and 90 degrees.
  • the thin-film Nitinol had a percent metal coverage of between 14% and 21%, and an edge density of between 23 mm of edge per mm 2 of surface area and 42 mm of edge per mm of surface area.
  • Figure 7C is an image showing results of the thin-film Nitinol covered stent having a higher pore density 8 weeks after implanting at the model aneurysm in a rabbit.
  • the thin-film Nitinol of this device was fabricated with a slit length of approximately 150 ⁇ .
  • the thin-film Nitinol had a pore density of approximately 150 pores/mm 2 as implanted.
  • the pore density of the thin-film Nitinol may range from 134 to 227 pores/mm 2 when the strut angle is between 30 and 90 degrees.
  • the thin-film Nitinol had a percent metal coverage of between 24% and 36%, and an edge density of between 40 mm of edge per mm 2 of surface area and 68 mm of edge per mm 2 of surface area.
  • thin-film mesh cover 215 composed of thin-film Nitinol having a pore density of between 50 and 500 pores/mm 2 (e.g., between 50 and 250 pores/mm 2 ) will facilitate rapid incorporation of a thin-film incorporated transcatheter heart valve such as thin-film transcatheter heart valve 200 into surrounding tissue.

Abstract

La présente invention concerne une valvule cardiaque transcathéter en couche mince comprenant une structure de support d'endoprothèse s'étendant le long d'un axe longitudinal et ayant une section transversale circulaire et un revêtement en maille en couche mince fenêtré ayant une section transversale circulaire et fixé à la structure de support d'endoprothèse. La valvule cardiaque transcathéter en couche mince peut en outre comprendre une valvule bioprothétique et/ou un revêtement polymère extérieur. Le revêtement en maille en couche mince fenêtré peut être formé par la gravure ionique réactive profonde d'un motif de rainures sur une surface d'un substrat, les rainures correspondant à des fenêtrages dans une structure de Nitinol souhaitée, le dépôt d'une couche de décollement sur la surface de substrat rainurée, le dépôt d'une première couche de Nitinol sur la couche de décollement, le soulèvement de la feuille en couche mince fenêtrée par gravure, la gravure supprimant la couche de décollement, et l'expansion de la feuille en couche mince fenêtrée pour étendre les fenêtrages.
PCT/US2017/032958 2016-05-17 2017-05-16 Valvule cardiaque transcathéter en couche mince WO2017201082A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1820077.4A GB2565028B (en) 2016-05-17 2017-05-16 Thin-film transcatheter heart valve

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662337801P 2016-05-17 2016-05-17
US62/337,801 2016-05-17

Publications (1)

Publication Number Publication Date
WO2017201082A1 true WO2017201082A1 (fr) 2017-11-23

Family

ID=60326366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/032958 WO2017201082A1 (fr) 2016-05-17 2017-05-16 Valvule cardiaque transcathéter en couche mince

Country Status (2)

Country Link
GB (1) GB2565028B (fr)
WO (1) WO2017201082A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10595994B1 (en) 2018-09-20 2020-03-24 Vdyne, Llc Side-delivered transcatheter heart valve replacement
US11071627B2 (en) 2018-10-18 2021-07-27 Vdyne, Inc. Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis
US11076956B2 (en) 2019-03-14 2021-08-03 Vdyne, Inc. Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis
US11109969B2 (en) 2018-10-22 2021-09-07 Vdyne, Inc. Guidewire delivery of transcatheter heart valve
US11166814B2 (en) 2019-08-20 2021-11-09 Vdyne, Inc. Delivery and retrieval devices and methods for side-deliverable transcatheter prosthetic valves
US11173027B2 (en) 2019-03-14 2021-11-16 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
US11185409B2 (en) 2019-01-26 2021-11-30 Vdyne, Inc. Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis
US11202706B2 (en) 2019-05-04 2021-12-21 Vdyne, Inc. Cinch device and method for deployment of a side-delivered prosthetic heart valve in a native annulus
US11234813B2 (en) 2020-01-17 2022-02-01 Vdyne, Inc. Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery
US11253359B2 (en) 2018-12-20 2022-02-22 Vdyne, Inc. Proximal tab for side-delivered transcatheter heart valves and methods of delivery
US11273032B2 (en) 2019-01-26 2022-03-15 Vdyne, Inc. Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis
US11273033B2 (en) 2018-09-20 2022-03-15 Vdyne, Inc. Side-delivered transcatheter heart valve replacement
US11278437B2 (en) 2018-12-08 2022-03-22 Vdyne, Inc. Compression capable annular frames for side delivery of transcatheter heart valve replacement
US11298227B2 (en) 2019-03-05 2022-04-12 Vdyne, Inc. Tricuspid regurgitation control devices for orthogonal transcatheter heart valve prosthesis
US11331186B2 (en) 2019-08-26 2022-05-17 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
US11344413B2 (en) 2018-09-20 2022-05-31 Vdyne, Inc. Transcatheter deliverable prosthetic heart valves and methods of delivery
US11786366B2 (en) 2018-04-04 2023-10-17 Vdyne, Inc. Devices and methods for anchoring transcatheter heart valve

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143817A1 (en) * 2003-11-10 2005-06-30 Angiotech International Ag Medical implants and anti-scarring agents
US8017396B2 (en) * 2008-02-22 2011-09-13 Vijay Kumar Cellulose based heart valve prosthesis
US20140005714A1 (en) * 2012-01-06 2014-01-02 Inceptus Medical, Inc. Multilayered expandable braided devices and methods of use
US20140172082A1 (en) * 2012-12-19 2014-06-19 W. L. Gore & Associates, Inc. Prosthetic heart valve with leaflet shelving

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014005395A2 (pt) * 2011-09-09 2017-03-28 Endoluminal Sciences Pty Ltd hidrogel biocompatível ou espuma, selagem endoluminal e método para selar um lúmen
US9155616B2 (en) * 2013-02-28 2015-10-13 St. Jude Medical, Cardiology Division, Inc. Prosthetic heart valve with expandable microspheres
US9636222B2 (en) * 2013-03-12 2017-05-02 St. Jude Medical, Cardiology Division, Inc. Paravalvular leak protection
EP3121973B1 (fr) * 2014-03-18 2018-03-07 Huawei Technologies Co., Ltd. Procédé, dispositif et système pour sélection de direction directionnelle
EP3125827B1 (fr) * 2014-04-01 2021-09-15 Medtronic CV Luxembourg S.à.r.l. Composant anti-fuite paravalvulaire pour prothèse de valvule transcathéter

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143817A1 (en) * 2003-11-10 2005-06-30 Angiotech International Ag Medical implants and anti-scarring agents
US8017396B2 (en) * 2008-02-22 2011-09-13 Vijay Kumar Cellulose based heart valve prosthesis
US20140005714A1 (en) * 2012-01-06 2014-01-02 Inceptus Medical, Inc. Multilayered expandable braided devices and methods of use
US20140172082A1 (en) * 2012-12-19 2014-06-19 W. L. Gore & Associates, Inc. Prosthetic heart valve with leaflet shelving

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786366B2 (en) 2018-04-04 2023-10-17 Vdyne, Inc. Devices and methods for anchoring transcatheter heart valve
US11344413B2 (en) 2018-09-20 2022-05-31 Vdyne, Inc. Transcatheter deliverable prosthetic heart valves and methods of delivery
US11273033B2 (en) 2018-09-20 2022-03-15 Vdyne, Inc. Side-delivered transcatheter heart valve replacement
US10595994B1 (en) 2018-09-20 2020-03-24 Vdyne, Llc Side-delivered transcatheter heart valve replacement
US11071627B2 (en) 2018-10-18 2021-07-27 Vdyne, Inc. Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis
US11109969B2 (en) 2018-10-22 2021-09-07 Vdyne, Inc. Guidewire delivery of transcatheter heart valve
US11278437B2 (en) 2018-12-08 2022-03-22 Vdyne, Inc. Compression capable annular frames for side delivery of transcatheter heart valve replacement
US11253359B2 (en) 2018-12-20 2022-02-22 Vdyne, Inc. Proximal tab for side-delivered transcatheter heart valves and methods of delivery
US11185409B2 (en) 2019-01-26 2021-11-30 Vdyne, Inc. Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis
US11273032B2 (en) 2019-01-26 2022-03-15 Vdyne, Inc. Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis
US11298227B2 (en) 2019-03-05 2022-04-12 Vdyne, Inc. Tricuspid regurgitation control devices for orthogonal transcatheter heart valve prosthesis
US11173027B2 (en) 2019-03-14 2021-11-16 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
US11076956B2 (en) 2019-03-14 2021-08-03 Vdyne, Inc. Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis
US11202706B2 (en) 2019-05-04 2021-12-21 Vdyne, Inc. Cinch device and method for deployment of a side-delivered prosthetic heart valve in a native annulus
US11179239B2 (en) 2019-08-20 2021-11-23 Vdyne, Inc. Delivery and retrieval devices and methods for side-deliverable transcatheter prosthetic valves
US11166814B2 (en) 2019-08-20 2021-11-09 Vdyne, Inc. Delivery and retrieval devices and methods for side-deliverable transcatheter prosthetic valves
US11331186B2 (en) 2019-08-26 2022-05-17 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
US11234813B2 (en) 2020-01-17 2022-02-01 Vdyne, Inc. Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery

Also Published As

Publication number Publication date
GB201820077D0 (en) 2019-01-23
GB2565028A (en) 2019-01-30
GB2565028B (en) 2021-09-15

Similar Documents

Publication Publication Date Title
WO2017201082A1 (fr) Valvule cardiaque transcathéter en couche mince
US20190209180A1 (en) Thin-film micromesh occlusion devices and related methods
ES2338560T3 (es) Implantes metalicos implantables y procedimientos para fabricarlos.
US20200222214A1 (en) Vascular implants and methods of fabricating the same
US11690632B2 (en) Intrasaccular thin-film flow diverters and related methods
US11865019B2 (en) Stent having adjacent elements connected by narrow flexible webs
US7811300B2 (en) Thin film devices for temporary or permanent occlusion of a vessel
JP4248151B2 (ja) ステントの部分的封入
US7736687B2 (en) Methods of making medical devices
US11020254B2 (en) Thin-film micromesh covers for medical devices and related methods
EP1923025B1 (fr) Endoprothèse vasculaire ayant un passage réduit d'emboli
CN108882941B (zh) 具有内皮化促进表面的生物可吸收的左心耳闭合
US20070150051A1 (en) Vascular implants and methods of fabricating the same
US20080004653A1 (en) Thin Film Devices for Occlusion of a Vessel
US10932896B2 (en) Thin-film cuff for endothelialization of endovascular grafts
US20190201220A1 (en) Three-dimensional thin-film nitinol devices
US20230270540A1 (en) Prosthetic heart valves with hermetic layers or valvular structures to reduce thrombosis risk
US20210196489A1 (en) Thin-film micromesh and related methods

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17800034

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 201820077

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20170516

122 Ep: pct application non-entry in european phase

Ref document number: 17800034

Country of ref document: EP

Kind code of ref document: A1